Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial

The Lancet Infectious Diseases 2026

View at publisher
Authors: Frank Bähner, Saul N. Faust, Leela R L Davies, Olga Blokhina, Donald M. Brandon, William B Smith, Vengalil Krishna K Chatterjee, Hana Hassanin, Tara M. Babu, Adam Zuiani, Susanne Steinhauser, Asaf Poran
+8 more Claire Brittain, Eric M. Mucker, Jay W. Hooper, Robbert van der Most, Pedro L Alonso, Özlem Türeci, Federico Mensa, Uğur Şahin
DOI: 10.1016/s1473-3099(26)00177-5
Cited by: 1
References: 20

Fields of Study & Subjects

Poxvirus research and outbreaks Immunotherapy and Immune Responses T-cell and B-cell Immunology

Publication details

Journal / source
The Lancet Infectious Diseases
Publisher
Elsevier BV
Volume
26
Issue
10
Pages
1045-1057
Publication date
1 June 2026
Language
EN